# Role of Health Technology Assessment in Cancer Drug Funding Decisions

**October 25, 1-4pm**

**Grand Hotel & Suites Toronto**  
225 Jarvis Street  
Toronto, ON, M5B 2C1

## Tuesday, October 25

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 pm – 1:00 pm</td>
<td>Registration</td>
</tr>
</tbody>
</table>
| 1:00 pm – 1:10 pm | **Welcoming Remarks/Introductions**  
Ken Bond, Director, Patient Engagement and International Affairs (CADTH) |
| 1:10pm – 1:20 pm | **Health Technology Assessment: CCAN Member Engagement and Perspectives**  
Marjorie Morrison, CEO, Canadian Cancer Action Network |
| 1:20 pm – 1:35 pm | **pan-Canadian Oncology Drug Review: How Cancer Drugs are Reviewed and Approved in Canada**  
Alex Chambers, Director, pCODR (CADTH) |
| 1:35 pm – 1:50 pm | **How Costs and Benefits Fit into the pCODR Process**  
Wanrudee Isaranuwatchai, Health Economist, St. Michael’s Hospital |
| 1:50 pm – 2:05 pm | **How to Prepare a High-Quality Patient Submission**  
Robin Markowitz, CEO, Lymphoma Canada |
| 2:05 pm – 2:15 pm | **Health Technology Assessment Patient Engagement Navigator: A New Resource**  
Adam Waiser, HTAPEN, Canadian Cancer Action Network |
| 2:15 pm – 2:35 pm | **A Review of the pERC Deliberative Framework: How Patient Input is Used in pERC Recommendations**  
Carole McMahon & Valerie McDonald, Patient Members, pERC (CADTH) |
| 2:35 pm – 2:45 pm | **BREAK**                                                                                     |
| 2:45 pm – 3:55 pm | **Case Study: Applying A Deliberative Framework for a Cancer Drug Recommendation**  
All participants  
Moderated by Helen Mai, Policy and Strategy Analyst, pCODR (CADTH) |
| 3:55 pm – 4:00 pm | **Closing Comments**  
Marjorie Morrison, CEO, Canadian Cancer Action Network |